An Open-Label, Multicenter Study to Assess the Efficacy of Switching to a Combination tablet Ezetimibe/Simvastatin 10mg/40mg, Compared to Doubling the Dose of Statin in Patients Hospitalized With a Coronary Event

Registry ID
EUCTR2004-002345-12
Source registry
EUCTR
Status
Completed
Phase
PHASE3
Sponsor
Merck & Co. Inc.
Start date
2005-01-26
Last update
2026-08-16

Conditions

Summary

Main objective : In patients taking a statin and admitted to a hospital for investigation of a coronary event, to evaluate the efficacy of switching to ezetimibe/simvastatin (10mg/40mg) on discharge compared to doucling the statin dose as added by the LDL-C values achieved after 12 weeks of treatment.

Locations

View on source registry